Article Sidebar
Article Details
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publishing rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
Read more here: http://creativecommons.org/licenses/by/4.0/.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.
Main Article Content
Boosting protease inhibitors with low-dose ritonavir - unravelling the mystery
Abstract
The advent of highly active antiretroviral treatment (HAART) has had the dramatic effect of changing HIV infection from a relentlessly progressive disease with inevitable death to a disease that is chronic and manageable. The goal of HAART is to suppress HIV replication maximally, and thereby restore immunological function, reduce HIV-related morbidity and mortality, and improve quality of life.1 HIV-infected persons who qualify for treatment can be treated with a HAART regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).2
Southern African Journal of HIV Medicine Vol. 7 (3) 2006: pp. 23-26
